OLDWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten registered public offering...
from PR Newswire: https://ift.tt/31A7VbV
No comments:
Post a Comment